American Heart Journal
Volume 156, Issue 3 , Pages 528-536.e5 , September 2008

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial

  • The BARI 2D Study Group

      Affiliations

    • BARI 2D sites and Study Group are listed in the Appendix A available online.Reprint requests: Maria Mori Brooks, PhD, University of Pittsburgh, GSPH, A530 Crabtree Hall, Pittsburgh, PA 15261.Email: mbrooks@pitt.edu

Received 11 February 2008 ,Accepted 16 May 2008.

  • Image Result

    Flowchart of the enrollment process in the BARI 2D clinical trial.

    Flowchart of the enrollment process in the BARI 2D clinical trial.

  • Image Result

    The BARI 2D population categorized by race/ethnicity overall and stratified by region.

    The BARI 2D population categorized by race/ethnicity overall and stratified by region.

  • Image Result

    Observed combinations of cardiac risk factors and clinical history in the BARI 2D population.

    Observed combinations of cardiac risk factors and clinical history in the BARI 2D population.

  • Image Result

    Myocardial jeopardy index score distribution among patients in the PCI stratum (light bars) and CABG stratum (dark bars).

    Myocardial jeopardy index score distribution among patients in the PCI stratum (light bars) and CABG stratum (dark bars).

  • Image Result

    Frequency of total cholesterol ≥200 mg/dL, blood pressure ≥140/90 mm Hg, and current smoking in BARI 2D at baseline and in the NHANES 1999-2000 cohort. (Data from Imperatore et al. 14 )

    Frequency of total cholesterol ≥200 mg/dL, blood pressure ≥140/90 mm Hg, and current smoking in BARI 2D at baseline and in the NHANES 1999-2000 cohort. (Data from Imperatore et al. 14 )

 Writing group: Maria Mori Brooks, Gregory Barsness, Bernard Chaitman, Sheng-Chia Chung, David Faxon, Frederick Feit, Robert Frye, Saul Genuth, Jennifer Green, Mark Hlatky, Sheryl Kelsey, Frank Kennedy, Ronald Krone, Richard Nesto, Trevor Orchard, Robert O'Rourke, Charanjit Rihal, Jean-Claude Tardif.

 BARI 2D is funded by the National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804).

 BARI 2D receives significant supplemental funding from GlazoSmithKline (Collegeville, PA); Bristol-Myers Squibb Medical Imaging, Inc. (North Billerica, MA); Astellas Pharma US, Inc. (Deerfield, IL); Merck & Co., Inc. (Whitehouse Station, NJ); Abbott Laboratories, Inc. (Abbott Park, IL); and Pfizer, Inc (New York, NY), and generous support from Abbott Laboratories Ltd.; MediSense Products (Mississauga, Ontario, Canada); Bayer Diagnostics (Tarrytown, NY); Becton, Dickinson and Company (Franklin Lakes, NJ); J. R. Carlson Labs (Arlington Heights, IL); Centocor, Inc. (Malvern, PA); Eli Lilly and Company (Indianapolis, IN); LipoScience, Inc. (Raleigh, NC); Merck Sante (Lyon, France); Novartis Pharmaceuticals Corporation (East Hanover, NJ); and Novo Nordisk, Inc. (Princeton, NJ).

PII: S0002-8703(08)00387-6

doi: 10.1016/j.ahj.2008.05.015

American Heart Journal
Volume 156, Issue 3 , Pages 528-536.e5 , September 2008

Article Tools

* Image Usage & Resolution